Case Report
Treatment of Polymicrobial Osteomyelitis with Ceftolozane-Tazobactam: Case Report and Sensitivity Testing of Isolates
Table 2
Bone penetration of cephalosporins and
β-lactamase inhibitors [
12].
| | Time after last dose (hours) | Bone (mg/kg): serum concentration (mg/L) ratio | Method |
| Cephalosporins | Ceftriaxone | 0.2–8 | 0.07–0.17 | HPLC | Cefotaxime | 0.75–4 | 0.02–0.28 | Bioassay | Cefuroxime (osteomyelitis) | 1 | 0.04–0.08 | HPLC | Cefazolin | 0.9 | 0.179 | HPLC | Cefepime | 1-2 | 0.46–0.76 | HPLC | Ceftazidime (ischemic bone) | 1-2 | 0.04–0.08 | HPLC | Ceftazidime | 2 | 0.54 | Bioassay |
| β-Lactamase inhibitors | Clavulanic acid | 1 | 1.14–1.76 | Bioassay | Sulbactam | 0.25–4 | 0.17–0.71 | Gas chromatography | Tazobactam | 1.5 | 0.22–0.26 | HPLC |
|
|
Assumed bone density of 1 kg/L was assumed if not reported. HPLC: high-performance liquid chromatography.
|